BERLIN, Feb. 6, 2007 - Jerini AG announced today the
expansion of their current research collaboration with Baxter AG
for the development of a non-intravenous therapy for the treatment
of hemophilia. The companies have initiated two additional programs
aimed at novel targets, potentially offering new therapeutic
developments in the treatment of hemophilia. These new agreements,
along with the existing collaboration, focus on three specific
targets associated with the disease.

"We are very pleased with the successful progress in our
collaboration with Baxter and their decision to expand this
alliance. Our proprietary Peptides-to-Drugs (P2D) technology
platform offers a novel and highly effective approach in the
development of new therapeutic peptide-derived injectable and oral
compounds," said Jens Schneider-Mergener, Chief Executive Officer
at Jerini.

Under the terms of the expanded agreement, Jerini will receive
upfront payments and full time equivalents (FTE) funding for each
of the two new programs, with potential milestone payments for the
achievement of discovery, preclinical, and clinical goals as well
as royalties on eventual product sales. The original collaboration
between Baxter and Jerini was initiated in 2001 and expanded in
2004.

About Jerini AG

Jerini is a pharmaceutical company based in Berlin, Germany,
focusing on the discovery, development, and commercialization of
novel peptide-based drugs. The company pursues disease indications
which have limited or no treatment options and has built a drug
pipeline composed of its own programs, as well as others in
collaboration with partners. In September 2006, Jerini reported
Phase III clinical results of Icatibant in the subcutaneous
treatment of hereditary angioedema and plans to file marketing
authorization applications with the FDA and EMEA in the first half
of 2007. Based on its technology platform, Jerini has also
established several in-house development programs, which address
indications within ophthalmology, oncology, and inflammatory
therapeutic areas.